Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model

The oncolytic reovirus (RV) has demonstrated clinical efficacy and minimal toxicity in a variety of cancers, including multiple myeloma (MM). MM is a malignancy of plasma cells that is considered treatable but incurable because of the 90% relapse rate that is primarily from drug resistance. The syst...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Thirukkumaran, Chandini M., Shi, Zhong Qiao, Nuovo, Gerard J., Luider, Joanne, Kopciuk, Karen A., Dong, Yuan, Mostafa, Ahmed A., Thakur, Satbir, Gratton, Kathy, Yang, Ailian, Chin, Alex C., Coffey, Matt C., Jimenez-Zepeda, Victor H., Stewart, Douglas, Chesi, Marta, Bergsagel, P. Leif, Morris, Don
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2019
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6418503/
https://ncbi.nlm.nih.gov/pubmed/30850386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018025593
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires